EX-99.B 3 y51647ex99-b.txt CERTAIN SUPPLEMENTAL INFORMATION 1 Exhibit 99(b) MERCK & CO., INC. SECOND QUARTER
2Q `01 2Q `00 % CHG. ------------------------------------------------------------------------------------ TOTAL SALES $ 11,893.1 $ 9,477.1 25% ---------- ---------- TOTAL COSTS, EXPENSES, & OTHER $ 9,299.6 $ 6,999.8 ---------- ---------- Materials & Production 7,204.8 5,052.1 Marketing & Administrative 1,637.4 1,524.3 Research & Development 602.4 548.0 Equity Income From Affiliates (215.0) (211.8) Other (Income)/Expense, Net 70.0 87.2 PRE-TAX INCOME $ 2,593.5 $ 2,477.3 TAXES $ 778.1 $ 755.6 TAX RATE 30.0% 30.5% NET INCOME $ 1,815.4 $ 1,721.7 5% EPS - ASSUMING DILUTION $0.78 $0.73 7% AVG. # SHARES - ASSUMING DILUTION 2,328.2 2,345.7
2Q `01 % CHG. VOL PX FX ------- ------- ---- -- -- TOTAL SALES $11,890 25% 22 5 -2 ------- -- -- - -- Total U.S. and Foreign Sales 5,320 6% 7 2 -3 ------- -- -- - -- U.S. 3,350 6% 3 3 0 Foreign 1,970 5% 14 -1 -8 Other Medco Sales 6,570 48%
2 Exhibit 99(b) MERCK & CO., INC. SIX MONTHS YEAR TO DATE
2001 2000 % CHG. ------------------------------------------------------------------------------------- TOTAL SALES $ 23,238.2 $ 18,328.4 27% ---------- ---------- TOTAL COSTS, EXPENSES, & OTHER $ 18,277.2 $ 13,657.1 ---------- ---------- Materials & Production 14,251.3 9,885.5 Marketing & Administrative 3,143.6 2,941.4 Research & Development 1,149.8 1,071.7 Equity Income From Affiliates (393.6) (400.1) Other (Income)/Expense, Net 126.1 158.6 PRE-TAX INCOME $ 4,961.0 $ 4,671.3 TAXES $ 1,488.3 $ 1,450.0 TAX RATE 30.0% 31.0% NET INCOME $ 3,472.7 $ 3,221.3 8% EPS - ASSUMING DILUTION $1.49 $1.37 9% AVG. # SHARES - ASSUMING DILUTION 2,337.0 2,355.5
2001 % CHG. VOL PX FX ------- ------- ---- -- -- TOTAL SALES $23,235 27% 23 6 -2 ------- -- -- - -- Total U.S. and Foreign Sales 10,285 7% 9 1 -3 ------- -- -- - -- U.S. 6,505 7% 5 2 0 Foreign 3,780 6% 14 0 -8 Other Medco Sales 12,950 49%
3 Exhibit 99(b) MERCK & CO., INC. OTHER FINANCIAL DISCLOSURES SECOND QUARTER 2001 OTHER (INCOME)/EXPENSE, NET
2Q `01 2Q `00 YTD 2001 YTD 2000 ----------------------------------------------------------------------------------------------------- INTEREST INCOME $(129.6) $(107.0) $(265.7) $(201.7) INTEREST EXPENSE 122.7 116.0 233.4 233.3 EXCHANGE (GAINS)/LOSSES (7.5) (9.7) (20.1) (17.5) MINORITY INTERESTS 60.7 95.8 146.0 156.0 AMORTIZATION OF GOODWILL AND INTANGIBLES 80.5 78.6 161.1 157.4 Other, net (56.8) (86.5) (128.6) (168.9) --------------------------------------------------- TOTAL $ 70.0 $ 87.2 $126.1 $158.6
JOINT VENTURE SALES DETAIL All sales reported here are end-market JV sales, presented on a "NET" basis, rounded to the nearest $5 million.
MERIAL 2Q `01 2Q `00 YTD 2001 YTD 2000 -------------------------------------------------------------------------------------- IVOMEC, HEARTGARD, other avermectins $125 $150 $235 $255 FRONTLINE 125 120 240 185 Biologicals 90 80 170 160 Other Animal Health 55 50 100 100 Poultry Genetics 55 55 105 110 ---------------------------------------- TOTAL MERIAL SALES $450 $455 $850 $810
AVENTIS PASTEUR-MSD 2Q `01 2Q `00 YTD 2001 YTD 2000 -------------------------------------------------------------------------------------- HEPATITIS VACCINES $ 25 $ 35 $ 50 $ 75 VIRAL VACCINES 10 10 25 25 Other Vaccines 75 70 140 135 ---------------------------------------- TOTAL AP-MSD SALES $110 $115 $215 $235
TOTAL MEDCO PRESCRIPTION/CLAIMS VOLUME (in millions)
2001 2000 % CHG ------------------------------------------------- FIRST QUARTER 138 99 39% SECOND QUARTER 134 98 37% ------------------------- YEAR TO DATE 272 197 38%
4 Exhibit 99(b) MERCK & CO., INC. PRODUCT SALES DETAIL
2Q `01 vs. 2Q `00 ----------------------------------------------------------------- TOTAL TOTAL U.S. U.S. FOREIGN FOREIGN PRODUCT % CHG $ % CHG $ % CHG $ -------------------------------------------------------------------------------------------- VIOXX 53% $ 725 48% $555 70% $170 VASOTEC / VASERETIC -44% 295 -80% 45 -17% 250 PRINIVIL / PRINZIDE 27% 310 30% 285 0% 25 COZAAR / HYZAAR 23% 510 29% 225 19% 285 MEVACOR 0% 135 5% 115 -20% 20 ZOCOR 5% 1,360 5% 870 3% 490 AGGRASTAT -14% 30 0% 25 N/M 5 SINGULAIR 79% 375 88% 300 50% 75 MAXALT 60% 80 50% 60 N/M 20 PROPECIA 10% 55 20% 30 0% 25 PROSCAR 21% 145 45% 80 0% 65 PRIMAXIN -3% 155 11% 50 -9% 105 CANCIDAS N/M 10 N/M 5 N/M 5 PEPCID -49% 110 -54% 90 0% 20 FOSAMAX 51% 490 70% 375 10% 115 CRIXIVAN/STOCRIN -27% 95 -18% 45 -33% 50 TIMOPTIC/TIMOPTIC XE -15% 55 0% 15 -20% 40 TRUSOPT/COSOPT 17% 105 13% 45 20% 60 HEPATITIS VACCINES -6% 80 -6% 75 0% 5 VIRAL VACCINES 4% 140 4% 135 N/M 5 OTHER VACCINES N/M 25 N/M 15 N/M 10
NOTE: Product sales rounded to the nearest $5 million. N / M - Not Meaningful 5 Exhibit 99(b) MERCK & CO., INC. PRODUCT SALES DETAIL
6 MONTHS YTD 2001 OVER 2000 ---------------------------------------------------------------------- TOTAL TOTAL U.S. U.S. FOREIGN FOREIGN PRODUCT % CHG $ % CHG $ % CHG $ ------------------------------------------------------------------------------------------------ VIOXX 43% $1,210 33% $ 905 85% $305 VASOTEC / VASERETIC -45% 555 -82% 80 -16% 475 PRINIVIL / PRINZIDE 25% 675 29% 625 -9% 50 COZAAR / HYZAAR 15% 895 11% 365 18% 530 MEVACOR 8% 280 14% 240 -20% 40 ZOCOR 17% 2,875 25% 1,920 3% 955 AGGRASTAT -8% 60 -20% 40 33% 20 SINGULAIR 78% 675 83% 530 61% 145 MAXALT 50% 135 50% 105 50% 30 PROPECIA 5% 105 33% 60 -18% 45 PROSCAR 20% 270 40% 140 4% 130 PRIMAXIN -3% 300 0% 90 -5% 210 CANCIDAS N/M 15 N/M 10 N/M 5 PEPCID -30% 295 -32% 260 -13% 35 FOSAMAX 40% 840 51% 620 16% 220 CRIXIVAN/STOCRIN -19% 220 -19% 85 -18% 135 TIMOPTIC/TIMOPTIC XE -12% 115 -14% 30 -11% 85 TRUSOPT/COSOPT 14% 200 25% 100 5% 100 HEPATITIS VACCINES 3% 170 3% 155 0% 15 VIRAL VACCINES 6% 265 4% 245 N/M 20 OTHER VACCINES N/M 50 N/M 40 N/M 10
NOTE: Product sales rounded to the nearest $5 million. N / M - Not Meaningful